<DOC>
	<DOCNO>NCT00003108</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness cisplatin plus bryostatin 1 treat patient advanced cancer .</brief_summary>
	<brief_title>Cisplatin Plus Bryostatin 1 Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dose limit toxicity maximum tolerate dose combination bryostatin 1 cisplatin chemotherapy patient advance , incurable solid tumor . OUTLINE : This dose-escalation study . The first 4 cohort patient receive escalate dose cisplatin fix dose bryostatin 1 , follow 5 cohort receive escalate dose bryostatin 1 fix dose cisplatin . In first course , cisplatin give 2 hour infusion follow 24 hour continuous infusion bryostatin 1 . In subsequent course bryostatin 1 give first cisplatin afterwards . Treatment continue every 21 day patient stable respond disease . Dose escalation proceeds maximum tolerate dose ( MTD ) combination chemotherapy determine . The MTD define dose precede 2 patient experience dose limit toxicity . After MTD determine , additional 10 patient treat dose level . Patients follow 1 month . PROJECTED ACCRUAL : Approximately 24-30 patient accrue study .</detailed_description>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , incurable solid tumor unresectable distant metastasis effective therapy exist No active CNS metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 8 week Hematopoietic : WBC least 3000/mm3 Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL Transaminases great 2.5 time normal PT PTT great 1.25 time upper limit normal Renal : Creatinine great 1.4 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : No myocardial infarction within past 6 month No congestive heart failure serious arrhythmia require treatment Other : No great grade 2 neuropathy ( include hear loss ) No frequent vomit severe anorexia No recent loss great 10 % body weight Not pregnant nursing Fertile patient must use effective birth control least 6 month study No serious concurrent medical illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover toxic effect No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( least 6 week since prior mitomycin nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy : Concurrent hormonal therapy allow patient progressive disease receive hormonal therapy least three month Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiation therapy Surgery : At least 21 day since prior major surgery Other : Any drug affect hepatic renal function must give stable dose initiate patient enters study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>